[ad_1]
AB-729, 60 mg administered every 8 weeks, reached an average HBsAg drop of -1.87 log10 IU/mL at the 44th week, which is equivalent to 60 mg administered every 4 weeks
AB-729 caused 75% of treated subjects to drop HBsAg below 100 IU/ml, and increased HBV-specific immune responses in 3/5 of evaluable subjects
AB-729 causes a reduction in HBV RNA and all HBsAg isoforms, indicating a wide range of targets involved
AB-729 continues to show good safety and tolerability characteristics after 48 weeks of administration
AB-836 preclinical data show that compared with the previous generation of capsid inhibitors, it has the potential to improve efficacy and enhance drug resistance
The conference call and webcast are scheduled for Monday, June 28, 2021 at 8 a.m. Eastern Time
Warminster, Pennsylvania, June 26, 2021 (Global News Agency) – Arbutus Biopharma Corporation (NASDAQ:Abuse), a clinical-stage biopharmaceutical company that focuses on the development of treatments for chronic hepatitis B virus (HBV) infections and therapies for the treatment of coronavirus (including COVID-19). It announced today that it will publish five Paper Abstracts Association for the Study of the Liver (EASL) International Liver CongressTM value (International Labour Organization). The abstract includes an oral evening report (Presentation LBO-2764) by Professor Man-Fung Yuen, D.Sc., MD, Ph.D., Deputy Head of Department, Head of Department of Gastroenterology and Hepatology, Master of Knee (Presentation LBO-2764) Chee, Hong Kong University, the lead investigator of the AB-729 Phase 1a/1b clinical trial, entitled “Repeated administration of GalNAc-siRNA AB-729 in patients with chronic hepatitis B resulted in strong and sustained HBsAg inhibition.”
As introduced by Professor Yuen, AB-729 continues to show a strong average HBsAg reduction across all doses and dosing intervals, with good safety and tolerability characteristics, followed by a continuous plateau.
The average (range) change of HBsAg during repeated administration of AB-729:
| access | Queue E AB-729 60 mg Q4Wⱡ |
Queue F AB-729 60 mg Q8W |
Queue I AB-729 90 mg Q8W |
phosphorus value between queue |
| Week 16 | -1.44 (-0.71 to -1.95) |
-1.39 (-1.61 to -1.08) |
-1.63 (-0.89 to -2.44) |
phosphorus ≥ 0.4 |
| Week 24 | -1.84 (-0.99 to -2.31) |
-1.57 (-1.24 to -2.01) |
-1.79 (-1.22 to -2.46) |
phosphorus ≥ 0.2 |
| Week 32 | -1.84 (-0.94 to -2.36) |
-1.68 (-1.37 to -2.15) |
— |
The full story on Benzinga.com
[ad_2]
Source link
